BioSpace News Archive

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration (FDA) for AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM).

The global microwave ablation market was estimated at USD 133.41 million in 2021 and it is expected to surpass around USD 289.92 million by 2030, poised to grow at a CAGR of 9.01% from 2022 to 2030.

Pacylex, a clinical-stage N-myristoyltransferase (NMT) inhibitor company developing first-in-class therapies for leukemia, lymphoma, and solid tumor cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted PCLX-001 Fast Track Designation for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML).

AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American Society of Hematology (ASH) annual meeting (December 10-13) in New Orleans, Louisiana.

Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in fireside chats and one-on-one meetings at the following upcoming investor conferences:

Amedisys, Inc., a leading provider of home health, hospice, personal care and high-acuity care, names Scott Ginn, Executive Vice President and Chief Financial Officer, its Acting Chief Operating Officer, effective immediately.

Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended September 30, 2022 and provided an update on upcoming milestones.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced top-line long-term survival results for remestemcel-L from its pivotal Phase 3 trial in children with steroid-refractory acute graft-versus-host disease.

Guerbet LLC, the US affiliate of Guerbet will present data on Elucirem™ (gadopiclenol) injection, Dotarem® (gadoterate meglumine) injection and AI solutions at the 2022 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting.

Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announced the development of a new proprietary formulation – a TRPV1 agonist - administered intranasally as a spray, to treat idiopathic rhinitis.